Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Randomised, Double-masked (Sponsor Unmasked), Placebo-controlled, Parallel Group, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of TGM-148 in Healthy Participants

NCT07843368 is registered in ClinicalTrials.gov with Tangram Therapeutics Plc as lead sponsor.

NCT NCT07843368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07843368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Randomised, Double-masked (Sponsor Unmasked), Placebo-controlled, Parallel Group, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of TGM-148 in Healthy Participants
Lead sponsor
Tangram Therapeutics Plc
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
March 31, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants